|Day's Range||246.21 - 249.21|
|52 Week Range||184.50 - 261.27|
|PE Ratio (TTM)||7.69|
|Dividend & Yield||2.80 (1.12%)|
|1y Target Est||N/A|
Biopharmaceutical developer Sarepta Therapeutics Inc. named a company outsider as its new chief executive, tapping Douglas Ingram to lead the firm.
Sarepta Therapeutics Inc said on Wednesday it appointed Douglas Ingram as president and chief executive officer. Ingram, who previously held a senior executive position in Allergan Plc, will also be a ...
While the Republican-led Congress continues the push to repeal the Affordable Care Act, we still see challenges in passing any new legislation.